Abstract-A number of attempts to classify cancer samples using miRNA/gene expression profiles are known in literature. However, semi-supervised learning models have only been recently introduced to exploit the huge unlabeled expression profiles in enhancing sample classification. It is important to combine both miRNA and gene expression sets as that provides more information on the characteristics of cancer samples. The use of both of labeled and unlabeled miRNA and gene expression sets to enhance sample classification has not been explored yet.
INTRODUCTION
MicroRNAs (miRNAs) are short (19-25 nucleotides) noncoding single-stranded RNA molecules [1] , which are cleaved from 70-100 nucleotide miRNA precursors. miRNAs regulate gene expression either at the transcriptional or translational level [1] . Recent research has pointed out the success of using miRNA and gene expression datasets in cancer classification; miRNA profiles were used recently to discriminate malignancies of the breast, lung and pancreas in [2] . Enhancing the accuracy of cancer classifiers, based on miRNA, gene, or mRNA expressions, has been targeted in previous work ( [3] , [4] , [5] , [6] ). Random Forests and SVM have been used in classifying cancer in ( [7] , [8] , [9] , [10] ).
The idea of combining both labeled and unlabeled sets using semi-supervised machine learning approaches has been used to enhance classifiers in other domains like [11] and [12] and in biology domain like protein classification [13] and prediction of factor-gene interaction [14] . Microarray experiments are time consuming, expensive and limited, that is why usually the number of samples of microarray-based studies is small [15] . Thus, huge publicly available gene/miRNA expression sets with unlabeled samples are tempting to use for enriching training data of sample classifiers. Integrating both miRNA and mRNA expression profiles were thought to provide complementary information [4] , as miRNAs regulate gene expression at the posttranscriptional level.
Semi-supervised machine learning approaches are applied in this paper to discriminate cancer subtypes. Discriminating cancer subtypes helps in understanding the evolution of cancer and is used to find appropriate therapies.
In this paper, two semi-supervised machine learning approaches, namely self-learning [16] and co-training ( [17] , [18] ) are used to enhance the classification accuracy of cancer samples by combining both labeled and unlabeled miRNA and gene expression profiles. In self-learning, a classifier is initially constructed using the labeled miRNA/gene set, then its accuracy is enhanced by adding more data from unlabeled miRNA/gene sets. In co-training, two classifiers are trained; each is specific to a different source of expression data (gene or miRNA), termed as two views of the data. Based on the two views, two classifiers are constructed and then used to train each other. Exchanging information between the two classifiers requires a mapping from miRNA expression to gene expression or the opposite. A simple mapping is thus suggested based on known biological relations between miRNAs and their target genes.
The aforementioned classification approaches were evaluated using gene and miRNA expression profiles of three different cancer types: breast cancer, hepatocellular carcinoma (HCC) and lung cancer. The results show up to 20% improvement in F1-measure over Random Forests and SVM classifiers. Co-Training also outperforms Low Density Separation (LDS) approach by around 25% improvement in F1-measure in breast cancer.
The paper is organized as follows: section II discusses the related work, while section III describes the proposed approaches in details and section IV shows experimental results. Finally section V concludes the paper. rania.ibrahim.salama@gmail.com, noha.yousri@alexu.edu.eg, drmaismail@gmail.com and nagwamakky@alexu.edu.eg 1 Computer and Systems Engineering Department, Alexandria University.
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II. RELATED WORK
Using miRNA expression profiles to discriminate cancerous samples from normal ones, and to classify cancer into its subtypes, is an active research area and was applied to different cancer types as breast, lung and pancreatic in [2] . The previous papers used one of the following supervised machine learning techniques like SVM, Prediction Analysis of Microarrays (PAM) and compound covariate predictor.
Several attempts for enhancing cancer classifiers have been recently introduced ( [3] , [4] , [5] , [6] ). In [3] , number of feature selection methods, as Pearson's and Spearman's correlations, Euclidean distance and others are used to enhance cancer classifiers. Also different classification methods like KNN are used in [3] . The work has focused only on improving classifiers based on labeled samples of miRNA expression profiles and didn't use publicity available unlabeled sets. Also, gene expression profiles were not used to enhance miRNA based cancer samples classifiers. Enhancing the classification accuracy by building two classifiers one for miRNA data and another for mRNA data were explored in [4] and finally it combines the two classifiers using fusion decision rule. The drawback of the approach is that it assumes the existence of both miRNA and mRNA data for each patient and it just uses decision fusion rule to combine the classifiers decision without enhancing the classifiers themselves. Another work [5] has considered using discrete function learning (DFL) method on the miRNA expression pro les to nd a subset of miRNAs that are most related to cancer and then uses these miRNAs to build a classifier. The paper didn't combine multiple miRNA datasets or use gene expression datasets to enhance the classifier. Semi-supervised machine learning approaches were introduced in classifying expression sets by using LDS approach in [15] to enhance cancer recurrence classifiers. In [6] self-learning and co-training were applied using gene expression sets only. In co-training, the paper tries to split genes into independent sets, considers each set as an independent view and finally combines the co-training classifiers using ada-boosting approach. The main drawback of [15] and [6] is that they didn't use miRNA expression sets to enhance cancer classifiers.
Other semi-supervised machine learning approaches like self-learning and co-training were introduced in other domains. The heuristic approach of self-learning (also known as self-training) is one of the oldest approaches in semi-supervised learning and that was introduced in [16] . Self-learning was used in many applications as object detection [11] and word sense disambiguation [12] . Also, cotraining is a semi-supervised approach that appeared in [17] and [18] and is also used in applications as word sense disambiguation [19] and email classification [20] .
In this paper, self-learning and co-training approaches are used. Both approaches use unlabeled sets to enhance classifiers accuracy. Co-training also enhances the results by combining both miRNA and gene expression sets. The results show improvements over Random Forests, SVM classifiers and LDS approach.
III. SELF-LEARNING AND CO-TRAINING ADAPTATION TO
MIRNA/GENE BASED CLASSFICIATION In our problem, the objective of self-learning and cotraining is to construct a classifier to discriminate between different cancer subtypes, given the following:
• The expression vector of a sample i, denoted x i , is defined as follows:
Where is the expression value of the j th miRNA/gene, and M is the number of miRNAs/genes.
• N is the number of samples.
Two sets are used in both self-learning and co-training, which are defined as follows:
• A set of labeled samples L; Where y i is the cancer subtype label.
• A set of unlabeled samples U; The size of U is expected to be much larger than L (|U| >> |L|), which is expected to help enhancing the accuracy of the classifiers by adding more expression vectors to the training data. Increasing the number of unlabeled sets leads to higher enrichment in the training set. Moreover, increasing the overlap between the miRNAs/genes in the labeled and unlabeled sets leads to increasing the effect of adding the unlabeled sets.
The next sections explain how the two approaches are adapted to use the unlabeled set U to enhance the baseline classifier constructed based on L.
A. Self-Leanring Adaptation
The steps of adapting the self-learning approach are described as follows: a) Train an initial cancer subtype classifier using set L. b) Use the initial classifier to identify the subtype labels of unlabeled set U. c) Choose the most confident subset of cancer samples (U'), i.e. samples classified with a confidence greater than a given threshold ( ). d) Append the set of most confident samples to the initial training dataset to form a new training set (U' L) for re-training the classifier. e) Use the classifier constructed at step d to preform several iterations over the unlabeled set(s). At each iteration, re-apply steps b, c and d. The resulting classifier can then be used to classify new samples based on their miRNA/gene expression profiles. The confidence threshold should be appropriately selected. Decreasing can increase the false positives rate. On the other hand, increasing can result in restricting the learning process to the highly confident samples, typically the ones that are most similar to the training data, thus losing the benefit of including more training samples to the labeled data. Tuning parameter is thus important, since it affects the classifier's accuracy to choose the samples that will enhance the classifier. The next section explains the co-training idea and adaption.
B. Co-Training Adaptation
In this paper, the co-training approach is adapted to classify cancer subtypes by training two different classifiers; the first is based on the gene expression view and the second is based on the miRNA expression view. Each view captures a different perspective of the underlying biology of cancer and integrating them using the co-training approach exploits this information diversity to enhance the classification accuracy. The following steps describe co-training in details: a) Two initial cancer classifiers are separately constructed; one from the miRNA expression dataset (L miRNA ) and another one from the gene expression dataset (L gene ) using manually labeled cancer subtypes sets. b) Let the initial classifiers separately classify the unlabeled cancer miRNA/gene expression datasets (U miRNA / U gene ) into cancer subtypes. c) Choose the most confident labeled subtypes samples (U' miRNA & U' gene ) that have classification scores greater than . d) Retrieve miRNA-gene relations using miRanda. For the classifiers to train each other, miRNA expression should be mapped to gene expression and vice versa. miRNAs and their target genes databases are used to map the datasets. In our case, miRanda [21] database is used. e) Append the mapped miRNA expression sets to the gene expression training sets and the mapped gene expression sets to the miRNA expression training sets and re-train the classifiers. f) Use the classifier constructed at step e to perform several iterations over the unlabeled set(s). At each iteration, re-apply steps b, c, d and e. g) In step d, a mapping between the miRNA view and gene view is required. miRNAs and their target genes are related by a many to many relationship; multiple miRNAs target the same gene, and multiple genes are targeted by the same miRNA. For the classifier to exploit the two views, a miRNA expression vector is constructed from its target gene's expression vector. To map a gene to a miRNA, or the opposite, it is proposed to take the mean expression value of all miRNAs related to a gene, or the opposite, i.e. the mean expression value of all genes related to a miRNA. Experimental results show that taking the mean value of expressions has improved the classification accuracy. Part of the future work would be investigating the effect of using other methods as a mapping function. After the co-training process, the two classifiers can be used independently, one on gene expression profile and the other on miRNA expression profile of cancer samples. The next section shows the experimental results of both self-learning and co-training approaches.
IV. EXPERIMENTAL RESULTS
Two core classifiers of self-learning and co-training were used, which are Random Forests (RF) [22] and SVM. RF have been used in classifying cancer in [7] and [8] . RF implementation from the Weka repository [23] was used, and the number of decision trees was set to 10. SVM implementation was also used from the Weka repository [23] .
The approaches were evaluated using three cancer types, namely breast cancer, hepatocellular carcinoma (HCC) and lung cancer. miRNA based classifiers were constructed for breast cancer and HCC sets, while gene based classifiers were constructed for all 3 sets. In addition, self-learning and co-training were compared against LDS in breast cancer and HCC. LDS Matlab implementation was downloaded from [24] . Tables I and II show the size of the training and testing sets for each cancer type according to its subtypes. All miRNA and gene expression profiles were downloaded from NCBI [25] . Table III shows sample size and miRNA/gene numbers in the unlabeled sets.
Tables IV to VII show the detailed results of applying self-learning and co-training. The results show up to 20% improvement in F1-measure in breast cancer, 4% improvement in precision in HCC cancer and 3% improvement in F1-measure in lung cancer. Co-Training also outperforms LDS approach by around 25% improvement in F1-measure in breast cancer. The improvement in breast cancer was higher as the number of sets used was larger and the number of overlapping between miRNAs/genes of labeled and unlabeled sets was larger. 
V. CONCLUSION
In this paper, two semi-supervised machine learning approaches were adapted to classify cancer subtype based on miRNA and gene expression profiles. They both exploit the expression profiles of unlabeled samples to enrich the training data. Results show up to 20% improvement in F1-measure over Random Forests and SVM classifiers. Co-Training also outperforms Low Density Separation (LDS) approach by around 25% improvement in F1-measure in breast cancer.
